Suneva Medical, an aesthetics company focused on developing, manufacturing and commercializing novel, differentiated regenerative products for the aesthetic markets, agreed to go public via a SPAC merger with Viveon Health Acquisition, a special purpose acquisition company, in a $201m deal. “As an operator-run SPAC, Viveon was focused on identifying best-in-class management that possessed the skillset and execution plan to deliver robust revenue growth. The merger with Suneva demonstrates our confidence in their category-leading product portfolio and experienced management team to deliver on the next wave of growth in regenerative aesthetics. We believe that our sales channel development and operational background provides natural synergies with the Suneva team as we collectively grow the business and increase shareholder value,” Jagi Gill, Viveon Health CEO and Chairman.